Hymenoptera venom immunotherapy and field stings

Journal of Investigational Allergology and Clinical Immunology

Volumn 16, Issue 4, 2006, Pages 224-231

  Lang, R ^a   Hawranek, T ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Field sting; Hymenoptera venom allergy; Mast cell tryptase; Systemic allergic reaction; Venom immunotherapy

Indexed keywords

BEE VENOM; HYMENOPTERA VENOM; INSECT VENOM; TRYPTASE; UNCLASSIFIED DRUG; YELLOW JACKET VENOM;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; FIELD STUDY; HIGH RISK PATIENT; HUMAN; HYMENOPTERA; IMMUNOTHERAPY; INSECT STING; MALE; MAST CELL;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANIMALS; ARTHROPOD VENOMS; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYMENOPTERA; IMMUNOGLOBULIN E; INSECT BITES AND STINGS; MALE; MAST CELLS; MIDDLE AGED; RISK FACTORS; SERINE ENDOPEPTIDASES; TIME FACTORS; TRYPTASES;

EID: 33746881491     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Müller U, Mosbech H. Immunotherapy with Hymenoptera venoms. Allergy. 1993; 48:36-46.
2. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med. 1978; 299:157-61.
3. Müller U, Thurnheer U, Patrizzi R, Spiess J, Hoigne R. Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy. 1979; 34:369-78.
4. Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: Results of re-stings in 200 patients. J Allergy Clin Immunol. 1998; 101:606-12.
5. Graft DF, Golden DBK, Reisman RE, Valentine MD, Yunginger JW. Position statement: the discontinuation of Hymenoptera venom immunotherapy. Report from the Committee on Insects. J Allergy Clin Immunol. 1998; 101:573-5.
6. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: Outcome after five years. J Allergy Clin Immunol. 1996; 97:579-87.
7. van Halteren HK, van der Linden PWG, Burgers JA, Bartelink AKM. Discontinuation of yellow jacket venom immunotherapy: Follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol. 1997; 100:767-70.
8. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: Extended observations. J Allergy Clin Immunol. 1998; 101:298-305.
9. Reismann RE. Duration of venom immunotherapy: relationship to the severe symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol. 1993; 92:831-6.
10. Przybilla B, Ring L, Grießhammer B, Braun-Falco O. Schnellhyposensibilisierung mit Hymenopterengiften. Verträglichkeit und Therapieerfolg. Dtsch Med Wochenschr. 1987; 112:416-24.
11. Golden DBK, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol. 2000; 105:385-90.
12. Ruëff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol. 2001; 108:1027-32.
13. Müller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol. 1991; 87:702-9.
14. Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger, JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol. 1991; 88:339-48.
15. Franken HH, Dubois AE, Minkema HJ, van der Heide S, de Monchy JG. Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity. J Allergy Clin Immunol. 1994; 93:431-6.
16. Oude Elberink JNG, de Monchy JGR, Kors JW, van Doormaal JJ, Dubois AEJ. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol. 1997; 99:153-4.
17. Ludolph-Hauser D, Ruëff F, Fries C, Schöpf P, Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet. 2001; 357:361-2.
18. Haeberli G, Brönnimann M, Hunziker T, Müller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy. 2003; 33:1216-20.
19. Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res. 1966; 3:331-3.
20. Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol. 1992; 89:529-35.
21. Urbanek R, Forster J, Kuhn W, Ziupa J. Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr. 1985; 107:367-71.
22. Randolph CC, Reisman RE. Evaluation of decline in serum venom-specific IgE as a criterion for stopping venom immunotherapy. J Allergy Clin Immunol. 1986; 77: 823-827.
23. Haugaard L, Nørregaard OF, Dahl R. In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol. 1991; 87:699-702.
24. Graft DF, Schoenwetter WF. Insect sting allergy: analysis of a cohort of patients who initiated venom immunotherapy from 1978 to 1986. Ann Allergy. 1994; 73:481-5.
25. Hoffman DR, Jacobson RS. Allergens in hymenoptera venom XII: how much protein is in a sting? Ann Allergy. 1984; 52:276-8.
26. Reisman RE. Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. J Allergy Clin Immunol. 1992; 90:335-9.
27. van der Linden PW, Hack CE, Struyvenberg A, van der Zwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol. 1994; 94:151-9.
28. Light WC. Insect sting fatality 9 years after venom treatment (venom allergy, fatality). J Allergy Clin Immunol. 2001; 107:925.
29. Reisman RE, Lantner R. Further observations of stopping venom immunotherapy: comparison of patients stopped because of a fall in serum venom-specific IgE to insignificant levels with patients stopped prematurely by self-choice. J Allergy Clin Immunol. 1989; 83:1049-54.
30. Dubois AE. Investigational and clinical use of the sting challenge. Curr Opin Allergy Clin Immunol. 2003; 3:283-5.
31. Biedermann T, Ruëff F, Sander CA, Przybilla B. Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels. Br J Dermatol. 1999; 141:1110-12.
32. Fricker M, Helbling A, Schwartz L, Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol. 1997; 100:11-15.